Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CCR1 | P32246 | 1/20 | 0.40 |
| ▸ | SOS2 | Q07890 | 1/20 | 0.39 |
| ▸ | CTSK | P43235 | 1/20 | 0.38 |
| ▸ | CTSS | P25774 | 2/20 | 0.37 |
| ▸ | IRAK4 | Q9NWZ3 | 1/20 | 0.35 |
| ▸ | GABRA5 | P31644 | 1/20 | 0.34 |
| ▸ | PRMT5 | O14744 | 1/20 | 0.33 |
| ▸ | WDR77 | Q9BQA1 | 1/20 | 0.33 |
| ▸ | ALOX5AP | P20292 | 2/20 | 0.32 |
| ▸ | FEN1 | P39748 | 2/20 | 0.32 |
| ▸ | AHR | P35869 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29413281 | 1.00 | CCR1 (0.40) | CCR1SOS2CTSKCTSSIRAK4 | |
| SCHEMBL14732983 | 0.83 | KCNH2 (0.44) | SOS2CTSKCTSSIRAK4 | |
| SCHEMBL22120171 | 0.82 | KCNH2 (0.52) | SOS2CTSKCTSS | |
| SCHEMBL3760158 | 0.79 | IRAK4 (0.49) | SOS2CTSKCTSSIRAK4PRMT5 | |
| SCHEMBL9297038 | 0.79 | SOS2 (0.39) | SOS2CTSKCTSSIRAK4PRMT5 | |
| SCHEMBL129485 | 0.79 | SOS2 (0.39) | SOS2CTSKCTSSIRAK4PRMT5 | |
| SCHEMBL1758823 | 0.79 | SOS2 (0.43) | CCR1SOS2CTSKCTSSPRMT5 | |
| SCHEMBL29561378 | 0.79 | SOS2 (0.39) | SOS2CTSKCTSSIRAK4PRMT5 | |
| SCHEMBL2954219 | 0.79 | HSD11B1 (0.41) | SOS2CTSKCTSSIRAK4GABRA5 | |
| SCHEMBL17771959 | 0.79 | SOS2 (0.39) | SOS2CTSKCTSSIRAK4PRMT5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 89 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12590062-B2 | PD-1/PD-L1 inhibitors | GILEAD SCIENCES, INC. (US) | 2026-03-31 | — | — | US | disclosed |
| US-12473314-B2 | Phospholipid compounds and uses thereof | GILEAD SCIENCES, INC. (US) | 2025-11-18 | — | — | US | disclosed |
| EP-4537828-A2 | PHOSPHOLIPID COMPOUNDS AND USES THEREOF | Gilead Sciences, Inc. (US) | 2025-04-16 | — | — | EP | disclosed |
| EP-4200301-B1 | PHOSPHOLIPID COMPOUNDS AND USES THEREOF | GILEAD SCIENCES INC (US) | 2025-02-26 | — | — | EP | disclosed |
| US-12030904-B2 | Phospholipid compounds and uses thereof | GILEAD SCIENCES, INC. (US) | 2024-07-09 | — | — | US | disclosed |
| EP-4352059-A1 | TRICYCLIC HETEROCYCLES AS FGFR INHIBITORS | Incyte Corporation (US) | 2024-04-17 | — | — | EP | disclosed |
| CN-114276349-B | 2-aminopterine derivatives or salts thereof, and preparation method and application thereof | 复旦大学 | 2024-04-09 | — | — | CN | disclosed |
| US-11939331-B2 | Tricyclic heterocycles as FGFR inhibitors | INCYTE CORPORATION (US) | 2024-03-26 | — | — | US | disclosed |
| US-20240025932-A1 | PHOSPHOLIPID COMPOUNDS AND USES THEREOF | GILEAD SCIENCES, INC. | 2024-01-25 | — | — | US | disclosed |
| US-11866431-B2 | Bicyclic compounds | VIVACE THERAPEUTICS, INC. (US) | 2024-01-09 | — | — | US | disclosed |
| EP-1954274-A4 | SUBSTITUTED QUINOLONES AND METHODS OF USE | CHEMOCENTRYX INC (US) | 2009-01-07 | — | — | EP | disclosed |
| WO-2008107478-A1 | QUINOLINONE DERIVATIVES AS PARP AND TANK INHIBITORS | JANSSEN PHARMACEUTICA NV (BE) | 2008-09-12 | — | — | WO | disclosed |
| EP-1954274-A2 | SUBSTITUTED QUINOLONES AND METHODS OF USE | ChemoCentryx Inc (US) | 2008-08-13 | — | — | EP | disclosed |
| EP-1942890-A2 | CHEMOKINE RECEPTOR BINDING COMPOUNDS | ANORMED INC. (CA) | 2008-07-16 | — | — | EP | disclosed |
| EP-1896023-A2 | CHEMOKINE RECEPTOR BINDING COMPOUNDS | ANORMED INC. (CA) | 2008-03-12 | — | — | EP | disclosed |
| US-20070167443-A1 | Substituted quinolones and methods of use | CHEMOCENTRYX, INC. (US) | 2007-07-19 | — | — | US | disclosed |
| WO-2007059108-A2 | SUBSTITUTED QUINOLONES AND METHODS OF USE | CHEMOCENTRYX, INC. (US) | 2007-05-24 | — | — | WO | disclosed |
| WO-2006138350-A2 | CHEMOKINE RECEPTOR BINDING COMPOUNDS | ANORMED INC. (CA) | 2006-12-28 | — | — | WO | disclosed |
| WO-2006138259-A2 | CHEMOKINE RECEPTOR BINDING COMPOUNDS | ANORMED INC. (CA) | 2006-12-28 | — | — | WO | disclosed |
| US-20050277668-A1 | viricide, antiinflammatory agent; autoimmune diseases; protective effects against infection of target cells by a human immunodeficiency virus (HIV); 6-Chloro-N-((R)-3-{4-[(4-methoxy-phenyl)-(4-methyl-pyridin-3-ylmethyl)-amino]-piperidin-1-yl}-butyl)-2,4-dimethyl-nicotinamide | ANORMED INC. | 2005-12-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11866431-B2 | Bicyclic compounds | YAP1, MYC, TEAD2 | CCR1 3822/4885SOS2 1041/4885CTSK 3064/4885 |
| US-20050277668-A1 | viricide, antiinflammatory agent; autoimmune diseases; protective effects against infection of target cells by a human immunodeficiency virus (HIV); 6-Chloro-N-((R)-3-{4-[(4-methoxy-phenyl)-(4-methyl-pyridin-3-ylmethyl)-amino]-piperidin-1-yl}-butyl)-2,4-dimethyl-nicotinamide | CCR5, CCR2, CXCR3 | CCR1 6/4885SOS2 4560/4885CTSK 3084/4885 |
| US-12030904-B2 | Phospholipid compounds and uses thereof | PHOSPHO1, SGMS2, SGMS1 | CCR1 2934/4885SOS2 1898/4885CTSK 1060/4885 |
| US-20070167443-A1 | Substituted quinolones and methods of use | TOP2A, NQO2, TOP2B | CCR1 3890/4885SOS2 1321/4885CTSK 2006/4885 |
| US-12590062-B2 | PD-1/PD-L1 inhibitors | CD274, PDCD1LG2, PDCD1 | CCR1 15/4885SOS2 2953/4885CTSK 4150/4885 |
| US-20240025932-A1 | PHOSPHOLIPID COMPOUNDS AND USES THEREOF | PHOSPHO1, SGMS2, SGMS1 | CCR1 2934/4885SOS2 1898/4885CTSK 1060/4885 |
| US-11939331-B2 | Tricyclic heterocycles as FGFR inhibitors | FGFR3, FGFR1, FGFR2 | CCR1 4519/4885SOS2 1667/4885CTSK 1002/4885 |
| US-12473314-B2 | Phospholipid compounds and uses thereof | PHOSPHO1, SGMS2, SGMS1 | CCR1 2934/4885SOS2 1898/4885CTSK 1060/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.